Annovis Secures Buntanetap Patent Ahead of Alzheimer’s Trial Data
MALVERN, PA — Annovis Bio Inc. (NYSE: ANVS) has secured U.S. patent protection through June 2044 for the formulation of its experimental Alzheimer’s and Parkinson’s treatment buntanetap, strengthening its intellectual …
Annovis Secures Buntanetap Patent Ahead of Alzheimer’s Trial Data Read More